Heidi Gallo
Adult Health · Louisville, KYNPI 1104807189
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,813 of the $15,112 with a category attached, or 84.8%. 35 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2022 at $5,787 and has fallen 89.2% since, to $623 in 2025. Among adult health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $38.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$3K
- GSK$2K
- Bayer$1K
- Biohaven Pharmaceuticals, Inc.$928
- Novo Nordisk$779
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$2,25015%
- Food & beverage$12,81385%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $4,298 |
| AstraZeneca | 72 | $3,208 |
| GSK | 60 | $1,740 |
| Bayer | 29 | $1,023 |
| Biohaven Pharmaceuticals, Inc. | 11 | $928 |
| Novo Nordisk | 22 | $779 |
| Phathom Pharmaceuticals, Inc. | 3 | $378 |
| Amgen | 10 | $353 |
| Idorsia Pharmaceuticals US Inc | 2 | $242 |
| Pfizer | 13 | $220 |
| Lilly USA, LLC | 13 | $200 |
| Boehringer Ingelheim | 12 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $182 |
| Ardelyx, Inc. | 3 | $159 |
| Mylan Specialty L.p. | 10 | $157 |
| Hologic Sales And Service, LLC | 1 | $136 |
| Astellas Pharma US Inc | 2 | $122 |
| Verona Pharma, Inc. | 1 | $121 |
| Johnson & Johnson | 1 | $109 |
| Electromed, Inc. | 8 | $105 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $67 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| IBSA Pharma Inc. | 4 | $58 |
| Dexcom, Inc. | 2 | $45 |
| Abbott | 2 | $34 |
| Antares Pharma, Inc. | 2 | $30 |
| Novartis | 2 | $26 |
| Grifols USA, LLC | 1 | $19 |
| Organon | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Pulmonx Corporation | 1 | $17 |
| Insulet Corporation | 1 | $15 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Bard Access Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,112 in reported general payments places this provider in the 95th percentile of 170 adult health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $57,124 |
| OzempicSemaglutide | 48 | $53,481 |
| FarxigaDapagliflozin Propanediol | 43 | $39,270 |
| TrulicityDulaglutide | 23 | $30,349 |
| JanuviaSitagliptin Phosphate | 21 | $21,129 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $17,612 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $13,090 |
| JardianceEmpagliflozin | 16 | $12,296 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $3,283 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,177 |
| Bupropion XlBupropion Hcl | 40 | $1,198 |
| Ezetimibe | 52 | $1,054 |
| Atorvastatin Calcium | 117 | $899 |
| Omeprazole | 92 | $894 |
| Ondansetron Hcl | 18 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,740 | $70,21462 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,208 | $56,88255 claims |
| Novo NordiskOzempic | $779 | $53,48148 claims |
| Lilly USA, LLCTrulicity | $200 | $30,34923 claims |
| Boehringer IngelheimJardiance | $195 | $12,29616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 adult health providers in Kentucky.
Other adult health in Louisville
- Stephanie FlaspoehlerLouisville$174K
- Karen EastridgeLouisville$10K
- Barbara CarpenterLouisville$8K
- Loren GarzaLouisville$6K
- Kelly MikeLouisville$4K
- Layla Al-ShamiLouisville$3K
- Brittany McWhorterLouisville$3K
- Lahoma PratherLouisville$2K
- William NapierLouisville$2K
- Barbara LemmonsLouisville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.